Corcept Therapeutics Incorporated (CORT) Cash Flow Statement

The 2026Q2 OCF/NI ratio of 0.80 marks a notable deterioration from the 1.58 and 2.77 ratios seen in the prior two quarters, indicating that the reported net income of $42.1M was not fully backed by cash from operations. The large negative working capital change of -$46.8M in the same quarter appears to be the primary driver, potentially reflecting timing of receivables or payables. Investors should monitor whether this is a one-off seasonal effect or a trend indicating lower earnings quality.

The FCF trajectory has been erratic, with a negative quarter in 2026Q1 followed by a rebound, but the overall trend suggests a deceleration from the robust FCF margins of 32.5% and 39.5% in 2024Q4 and 2024Q3, respectively. This compression appears to be driven by rising working capital outflows and increased cash taxes, rather than capex, which remains minimal. The company's ability to sustain its pipeline investment while maintaining positive FCF will be a key monitor.

With capex never exceeding $2.5M in any quarter, the company's capital intensity is negligible, consistent with a specialty pharma business that outsources manufacturing. The low capex means that free cash flow is almost entirely a function of operating cash flow, making working capital swings and non-cash charges the primary determinants of cash generation. This structure provides flexibility but also means that any future investment in internal manufacturing or commercial infrastructure would represent a significant shift.

The negative working capital change in 2026Q2 was the largest outflow in the ten-quarter period, and it contrasts with positive contributions in the prior two quarters. This volatility suggests that the company's cash conversion cycle is not stable, possibly due to specialty pharmacy distribution dynamics or rebate accruals. Analysts should adjust for these swings to assess the underlying cash-generating ability of the Korlym franchise.

The company has been aggressively repurchasing shares, with buybacks in 2025Q2 alone exceeding the quarter's free cash flow of $43.9M, suggesting the use of accumulated cash reserves. This deployment strategy may signal management's confidence in the intrinsic value of the stock, but it also reduces the cash buffer that could be used for strategic M&A or to weather a potential generic entry. The lack of dividends is consistent with a growth-oriented biotech.

The cumulative OCF/NI ratio of 1.42 over the ten-quarter period suggests that, despite quarterly volatility, the company has generated more cash than its reported net income, partly due to non-cash charges like stock-based compensation and depreciation. However, the recent quarters show a reversal, with OCF lagging net income, which may indicate a shift in working capital dynamics. This divergence warrants monitoring as it could signal a change in earnings quality.